Why Atherosclerosis Must Be Rewritten
The problem is not ignorance Medicine does not usually fail because it knows too little. It more often fails because it knows something well enough to stop asking. The history of atherosclerosis is a precise example of this dynamic. Over the second half of the twentieth century, clinical lipidology built a coherent and useful story. Large populations were followed. Serum cholesterol was measured. Risk gradients were documented. Statins were developed, tested in randomized trials, and shown to reduce cardiovascular events with a consistency that few drug classes have matched. The science was real. The clinical gains were real. The epidemiological framework was robust. And yet, two patients can sit in the same clinic, present nearly identical lipid panels, report similar diets, and carry similar cardiovascular risk scores—yet one will have advanced, rupture‑prone disease while the other will not. One will have a myocardial infarction in middle age. The other will reach late life w...